Factor V Leiden

Last updated: November 01, 2022

Factor V Leiden

ETP Hematological System

ETP Hematological System

Blood histology
Blood components
Erythropoietin
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
Plasmodium species (Malaria)
Anemia: Clinical
Microcytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Iron deficiency anemia
Sideroblastic anemia
Lead poisoning
Alpha-thalassemia
Beta-thalassemia
Macrocytic anemia: Pathology review
Megaloblastic anemia
Vitamin B12 deficiency
Folate (Vitamin B9) deficiency
Fanconi anemia
Diamond-Blackfan anemia
Anemia of chronic disease
Sickle cell disease (NORD)
Sickle cell disease: Clinical
Aplastic anemia
Acute intermittent porphyria
Porphyria cutanea tarda
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Autoimmune hemolytic anemia
Hemolytic disease of the newborn
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Paroxysmal nocturnal hemoglobinuria
Hereditary spherocytosis
Platelet disorders: Pathology review
Heparin-induced thrombocytopenia
Thrombotic thrombocytopenic purpura
Hemolytic-uremic syndrome
Glanzmann's thrombasthenia
Bernard-Soulier syndrome
Coagulation disorders: Pathology review
Hemophilia
Vitamin K deficiency
Mixed platelet and coagulation disorders: Pathology review
Disseminated intravascular coagulation
Von Willebrand disease
Thrombosis syndromes (hypercoagulability): Pathology review
Factor V Leiden
Protein C deficiency
Protein S deficiency
Antithrombin III deficiency
Hemochromatosis
Vasculitis: Pathology review
Vasculitis: Clinical
Shock: Pathology review
Antiphospholipid syndrome
Myeloproliferative disorders: Pathology review
Polycythemia vera (NORD)
Essential thrombocythemia (NORD)
Thrombocytopenia: Clinical
Myelofibrosis (NORD)
Langerhans cell histiocytosis
Lymphomas: Pathology review
Hodgkin lymphoma
Non-Hodgkin lymphoma
Lymphoma: Clinical
Leukemias: Pathology review
Acute leukemia
Chronic leukemia
Leukemia: Clinical
Leukemoid reaction
Myelodysplastic syndromes
Plasma cell disorders: Pathology review
Multiple myeloma
Waldenstrom macroglobulinemia
Monoclonal gammopathy of undetermined significance
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment

Transcript

Watch video only

Factor V Leiden is a disorder where blood clots form more easily due to a mutation in a clotting protein called factor V. Factor V Leiden is the most common hypercoagulable disorder in people of caucasian descent, and was named after the town Leiden in Holland, where the disease was first described.

Now, Factor V Leiden is a hemostasis disorder.

Hemostasis is the process where blood flow is stopped after there’s damage to a blood vessel, and it has two steps.

Primary hemostasis involves the formation of a platelet plug at the site of injury, and secondary hemostasis involves the coagulation cascade, where several clotting factors come into play to form a fibrin mesh over the platelet plug to reinforce it - forming a blood clot.

Hemostasis can be both stimulated, and inhibited by several factors.

One way to stimulate hemostasis is with thrombin, or factor II, which increases platelet activation, and cleaves several factors involved in secondary hemostasis to their active form.

So one way to inhibit hemostasis is actually to inhibit thrombin.

This happens with the help of anticoagulant proteins like protein C. Protein C is a vitamin K dependent circulating plasma protein produced in the liver along with a cofactor called protein S.

Both protein C and S interact with a protein called thrombomodulin, which is on the surface of intact endothelial cells that line our blood vessels.

So, let’s say you cut your finger and now a blood clot has formed.

When there’s a lot of thrombin around a damaged blood vessel, excess thrombin binds to thrombomodulin and it can no longer participate in the coagulation cascade.

So in a sense, the undamaged cells help ensure that the coagulation process is limited to the injury site.

Furthermore, the thrombin-thrombomodulin complex binds to protein C. Protein S then joins the party, forming a complex that includes protein C, protein S, and thrombin-thrombomodulin. Protein S binding to this complex activates the proteolytic site of protein C which then cleaves and inactivates active factor V, which is a cofactor for factor X in the common pathway of the coagulation cascade, as well as factor VIII, which is a cofactor for factor IX in the intrinsic pathway of the coagulation cascade.

This slows down coagulation. What is more, the factor V degradation product also binds to this complex and further enhances its ability to cleave more active factor V and active factor VIII, further limiting coagulation.

So anticoagulation prevents clots from growing too large and blocking blood flow to tissues supplied by the vessel.

It also prevents clots from getting so big that small parts of the growing clot break off in the form of emboli.

So with Factor V Leiden, both active factor V, termed Va and inactivated factor V become resistant to cleavage by activated protein C because of a mutation that results in a misshapen cleavage site.

So when activated protein C, protein S, and the thrombin-thrombomodulin complex binds and tries to cleave factor Va or inactivate factor V, it can't because the normal cleavage site isn’t there!

And when factor V can’t be inactivated, you guessed it - coagulation doesn’t slow down, so there’s increased blood clot formation.

Usually, these clots develop in the deep veins of the lower limbs, like the popliteal and femoral veins, causing a venous thromboembolism, where small parts of the clot can break off and travel to other organs, like the lungs, the brain or the liver, cutting off blood flow to those organs.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  3. "Harrison's Principles of Internal Medicine" McGraw-Hill (2004)
  4. "Factor V Leiden" Radiol Technol (2019)
  5. "Factor V Leiden thrombophilia" Genet Med (2011)
  6. "Factor V Leiden" The Journal of Perinatal & Neonatal Nursing (2003)
  7. "Diagnosis and management of<i>factor V Leiden</i>" Expert Review of Hematology (2016)